The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug ...

Naim Alkhouri, MD, spoke to the potential for glucagon-like peptide-1 (GLP-1) receptor agonists to transform the treatment ...

Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final resolution.

Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). In this ongoing phase 3, multicenter ...

“The results from this landmark study across 37 countries provide strong evidence that semaglutide can help patients with MASH by not only improving liver health, but also addressing the underlying ...

The Food and Drug Administration (“FDA”) has removed semaglutide from its drug shortage list after the agency determined the current supply of ...

social media and print are exempt. “It’s absurd that broadcasters are banned from airing political ads in the final days before an election, while unregulated digital platforms are free to ...

Last weekend, the company expanded the campaign to add full-page print ads in The New York Times, The Wall Street Journal, The Washington Post, The Detroit News, The Detroit Free Press and other ...

The Proposed Product and Goal bullet points: Paid monthly subscription offering that allows users to experience Facebook (and potentially our other apps) without ads. Goal: Provide an advertising ...